Limited efficacy of daratumumab in multiple myeloma with extramedullary disease
| Authors | |
|---|---|
| Year of publication | 2022 |
| Type | Peer-reviewed scientific article |
| Magazine / Source | Leukemia |
| MU Faculty or unit | |
| Citation | |
| web | https://www.nature.com/articles/s41375-021-01343-w |
| Doi | https://doi.org/10.1038/s41375-021-01343-w |
| Keywords | daratumumab; multiple myeloma; extramedullary disease; efficacy |
| Description | The treatment of multiple myeloma (MM) has changed substantially during the past two decades. The incorporation of novel agents into therapeutic strategies has resulted in prolonged overall survival of MM patients with approximately 15% of them being considered operationally cured. |
| Related projects: |